HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on KalVista Pharma (NASDAQ:KALV) and maintained a price target of $16.
July 10, 2023 | 10:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
KalVista Pharma's stock may see positive movement due to the reiterated 'Buy' rating and maintained price target by HC Wainwright & Co.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The 'Buy' rating suggests that the analyst believes KALV's stock will outperform the market, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100